Full-Time

Clinical & Regulatory Medical Writing Manager

Updated on 3/14/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$120.2k - $180.4kAnnually

+ Bonus + Equity Awards

Mid, Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This is a hybrid position which allows 2 days per week remote work and 3 days per week in the Boston Seaport office.

Category
Technical Writing
Content & Writing
Legal & Compliance
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Superior written and oral communication skills
  • Experience writing and editing clinical regulatory documents
  • Ability to analyze, interpret, and summarize moderately complex data
  • Broad understanding of drug development, clinical research, study designs, biostatistics, pharmacology, regulatory requirements, and medical terminology
  • Ability to manage project teams, form productive working relationships, and work through conflicts
  • Excellent project management and organizational skills
  • Ability to complete work in a resourceful, self-sufficient manner and design alternative approaches to achieve desired results, with some guidance and mentoring on new or complex issues
  • Initiative and creativity in solving routine problems that affect multiple documents and in identifying and contributing to improvements in cross-functional process
  • Advanced computer skills related to word processing, templates, table/figure creation, literature searches, electronic review systems, and document management systems; can act as a resource for others for these tools
  • Typically requires an MS, Ph.D. (or equivalent degree)
  • Typically requires 4+ years of experience authoring clinical & regulatory documents within pharmaceutical or CRO industry (or the equivalent combination of education and experience)
Responsibilities
  • Authors moderately complex clinical regulatory documents (e.g., including clinical study protocols, clinical study reports, investigator’s brochures, and sections of regulatory submissions) in partnership with key cross-functional stakeholders
  • Serves as the lead Medical Writing Scientist for moderately complex clinical studies
  • Supports Medical Lead with review and interpretation of clinical study data and addressing questions from study team members
  • Participates in developing key messages for moderately complex clinical regulatory documents
  • Ensures medical and scientific consistency between related documents or studies in a clinical program
  • Analyzes and interprets data thoroughly and critically to determine the best approach to composing each document
  • Contributes to product development plans (e.g., provide information from previous studies, provide scientific input, integrate and review data) and serves as coordinating author for product development plans
  • Participates in developing standard operating processes and related procedures
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna enhances its gene therapy capabilities.
  • Increased investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's global expansion includes a patient assistance program for Trikafta in South Africa.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II results for suzetrigine may delay its development.
  • The $1.07 billion Orna partnership could strain resources if unsuccessful.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target sickle cell disease and beta thalassemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.

Precision Medicine Online
Jan 7th, 2025
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).